Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.54 |
| ▸ | IKBKB | O14920 | 3/20 | 0.51 |
| ▸ | MPO | P05164 | 7/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6086912 | 0.84 | SLC6A4 (0.55) | SLC6A4IKBKBRIPK1OPRM1OPRK1 | |
| SCHEMBL6087789 | 0.84 | SLC6A4 (0.55) | SLC6A4IKBKBOPRM1OPRK1OPRL1 | |
| SCHEMBL6087284 | 0.80 | SLC6A4 (0.54) | SLC6A4IKBKBGPR84 | |
| SCHEMBL1413420 | 0.79 | HTR2C (0.58) | IKBKB | |
| SCHEMBL6812169 | 0.77 | HTR2C (0.59) | SLC6A4IKBKBMPOGPR84 | |
| SCHEMBL25253204 | 0.76 | SLC6A4 (0.57) | SLC6A4MPOGPR84 | |
| SCHEMBL12541089 | 0.76 | HCAR2 (0.48) | IKBKB | |
| SCHEMBL12539973 | 0.76 | HCAR2 (0.48) | IKBKB | |
| SCHEMBL12539971 | 0.76 | HCAR2 (0.48) | IKBKB | |
| SCHEMBL6088026 | 0.74 | IDO1 (0.56) | SLC6A4OPRM1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7049314-B2 | Sexual disorders; antidepressants; attention deficit hyperactivity, obsessive-compulsive, and/or post-traumatic stress disorder; drug abuse and addiction | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-23 | — | — | US | disclosed |
| US-20040077705-A1 | Cyclopentyl indole derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| WO-2004026236-A2 | CYCLOPENTYL INDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077705-A1 | Cyclopentyl indole derivatives | HTR5A, TPH1, TPH2 | SLC6A4 11/4885IKBKB 320/4885MPO 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.